Accelerate Diagnostics, Inc. (AXDXQ)

Market Cap	171.27K
Revenue (ttm)	11.70M
Net Income (ttm)	-50.05M
Shares Out	25.19M
EPS (ttm)	-2.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,359
Average Volume	80,748
Open	0.0060
Previous Close	0.0070
Day's Range	0.0054 - 0.0097
52-Week Range	0.0038 - 2.0900
Beta	-0.14
RSI	22.52
Earnings Date	Sep 18, 2025

About Accelerate Diagnostics

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing (AST) of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides Accelerate PhenoTest BC Kit, a test kit for the system, which is indicated as an aid, in conjuncti...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1982
• Employees: 107
• Stock Exchange: OTCMKTS
• Ticker Symbol: AXDXQ

Financial Performance

In 2024, Accelerate Diagnostics's revenue was $11.70 million, a decrease of -2.99% compared to the previous year's $12.06 million. Losses were -$50.05 million, -18.78% less than in 2023.